This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Prognosis

Authoring team

After the first seizure, for two years from then onwards, about 60 percent of the untreated persons will have no further seizures.(1)

Remissions (being free of seizures for 5 years, on or off treatment) will occur in about 70% of the patients with epilepsy.(1)

  • the rest of the 20-30% of people will develop chronic epilepsy, which is usually treated with Anti-epileptics (1)

People with epilepsy (PWE) have a higher mortality rate than the general population (2)

In a UK based study (2) number of deaths within the database increased by 69% between the first and last year of the study (2014 compared with 2004)

  • epilepsy was considered as a contributing cause in approximately 45% of deaths of PWE under 35
  • factors associated with increased risk of death included
    • attendance at emergency departments and/or emergency admissions
    • antiepileptic drug (AED) polytherapy
    • status epilepticus
    • depression
    • and injuries
  • no seizures in the prior year was associated with a reduced risk of death

UK Biobank study (n=329,432; 2699 with epilepsy) found pts with epilepsy had an increased risk of all cardiac arrhythmias (HR 1.36; 95% CI 1.21-1.53), atrial fibrillation (AF) (1.26) & other cardiac arrhythmias (1.56) especially in those using carbamazepine and valproic acid vs pts without epilepsy (3)

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.